Edinburgh Worldwide Inv Trust Half-year Report

Edinburgh Worldwide Inv Trust PLC
08 June 2023
 

RNS Announcement

 

Edinburgh Worldwide Investment Trust plc

Legal Entity Identifier: 213800JUA8RKIDDLH380

 

Regulated Information Classification: Interim Financial Report

 

Results for the six months to 30 April 2023

 

The Company is invested in a diversified portfolio of companies which individually offer significant long term growth potential and typically have a market capitalisation of less than US$5bn at the time of initial investment.

¾  Over the six month period, the Company's net asset value per share decreased by 7.5% while the comparative index* decreased by 1.5%. The share price fell by 13.6%. Over the five year period, the Company's net asset value per share increased by 21.8% while the comparative index* increased by 33.8%. The share price decreased by 4.8%. Invested gearing as at 30 April 2023 was 12.4%.

¾  The market environment remains largely as it was six months earlier: a dynamic post-pandemic adjustment period where companies and stock markets are navigating inflationary and geopolitical challenges. This is sculpting a new investment environment. One where capital is less freely available, the hurdle rate for returns is higher and the tolerance of uncertainty is markedly lower.

¾  The notable contributors to absolute returns over the period was led by Exact Sciences, a developer of non-invasive molecular tests for early cancer detection. Alnylam Pharmaceuticals, a developer of drugs focused on harnessing gene silencing technology, was the largest detractor to absolute returns. 44 names in the portfolio generated positive absolute returns in sterling terms over the six months. Eight stocks fell more than 50%.

¾  During the period, the Company bought back for treasury 2,865,382 shares. 16,334,054 shares were held in treasury as at 30 April 2023. As at close of business on 6 June 2023, the discount was 18.8%.

¾  The net revenue return per share was a negative 0.31p (six months to 30 April 2022: negative 0.23p). No interim dividend is being recommended.

¾  As at 30 April 2023 the Company's investment in unlisted companies was 20.9% of total assets (30 April 2022: 19.3%).

¾  The Board and Managers remain confident that the holdings in the portfolio represent a collection of some of the most exciting and transformational long-term investment opportunities available.

 

* Source: Baillie Gifford/Refinitiv and relevant underlying index providers. See disclaimer at the end of this announcement.

For a definition of terms see Glossary of Terms and Alternative Performance Measures at the end of this announcement.

Past performance is not a guide to future performance.

 

Edinburgh Worldwide aims to achieve long term capital growth by investing primarily in listed companies throughout the world. The Company has total assets of £808.8 million (before deduction of loans of £97million) as at 30 April 2023.

Edinburgh Worldwide is managed by Baillie Gifford, the Edinburgh based fund management group with around £233 billion under management and advice as at 7 June 2023.

 

Edinburgh Worldwide Investment Trust plc is a listed UK company. The value of its shares and any income from them can fall as well as rise and investors may not get back the amount invested. This is because the share price is determined by the changing conditions in the relevant stock markets in which the Company invests and by the supply and demand for the Company's shares. Investment in investment trusts should be regarded as medium to long-term. The Company's risk could be increased by its investment in unlisted investments. These assets may be more difficult to buy or sell, so changes in their prices may be greater. The Company is listed on the London Stock Exchange and is not authorised or regulated by the Financial Conduct Authority. You can find up to date performance information about Edinburgh Worldwide on the Edinburgh Worldwide page of the Managers' website at edinburghworldwide.co.uk

 

Neither the contents of the Managers' website nor the contents of any website accessible from hyperlinks on the Managers' website (or any other website) is incorporated into, or forms part of, this announcement.

 

7 June 2023

For further information please contact:

Anzelm Cydzik, Baillie Gifford & Co

Tel 0131 275 2000

 

Jonathan Atkins, Four Communications

Tel: 020 3103 9553 or 07872 495 396

 

The following is the unaudited Interim Financial Report for the six months to 30 April 2023 which was approved by the Board on 7 June 2023.

Responsibility Statement

 

We confirm that to the best of our knowledge:

a)  the condensed set of Financial Statements has been prepared in accordance with FRS 104 'Interim Financial Reporting';

b)  the Interim Management Report includes a fair review of the information required by Disclosure Guidance and Transparency Rule 4.2.7R (indication of important events during the first six months, their impact on the Financial Statements and a description of the principal risks and uncertainties for the remaining six months of the year); and

c)  the Interim Financial Report includes a fair review of the information required by Disclosure Guidance and Transparency Rule 4.2.8R (disclosure of related party transactions and changes therein).

 

On behalf of the Board

Henry CT Strutt

Chairman

7 June 2023

 

Interim Management Report

 

Over the six months to 30 April 2023, the Company's net asset value per share* decreased by 7.5%, which compares to a fall of 1.5% in the S&P Global Smaller Companies Index, total return in sterling terms, over the same period. The share price over the six months fell by 13.6% to 149.20p representing a discount of 18.4% to the net asset value at 30 April 2023. This compares to a 12.7% discount at the beginning of the period. The Company buys back its own shares when the discount is substantial in absolute terms and relative to its peers; 2,865,382 shares were bought back in the period and are held in treasury.

Over the five-year period to 30 April 2023, the Company's net asset value per share* increased by 21.8% while the comparative index increased by 33.8%. The share price decreased by 4.8% over this period.

The market environment remains largely as discussed in the 2022 Annual Report: a dynamic post-pandemic adjustment period where companies and stock markets are navigating inflationary and geopolitical challenges. This is sculpting a new investment environment. One where capital is less freely available, the hurdle rate for returns is higher and the tolerance of uncertainty is markedly lower. The immediate manifestation of this is a shortening of the time horizons of many investors, lulling them into a mindset where the near-term resiliency of what they invest in is paramount and the future is approached with a large dose of pessimism.

We are unashamedly long-term investors with our analytical radar tuned towards high-potential early-stage growth opportunities. The current myopic environment described above is not conducive to our approach. We are accustomed to having a time horizon and investment style that can be out of sync with broader equity markets. In many ways, this seems an unavoidable aspect of contemporary equity investing. As bruising as this can feel in the near term, it ultimately creates the opportunity. It shapes the returns available to those willing to postulate how industries might evolve and actively seek out those companies driving that change.

For such companies, it's the fundamental path of progress that ultimately matters most not the prevailing stock market narrative. That progress naturally takes time to manifest but we remain confident that the holdings in the portfolio represent a collection of some of the most exciting and transformational long-term investment opportunities available.

Some Reflections on Growth and Technology

We have frequently noted how innovation and the application of technology is a structural force that largely sits outside of conventional business cyclicality. But recent headlines on technology sector job losses and retrenchment indicate that many tech-led companies have not been immune from current pressures. In some cases, the reasons for this cyclicality directly relate to end product demand, but in many other areas we suspect it represents a period of adaption to a new normal that we would ultimately expect to see replicated more broadly across the economy.

That 'new normal' will likely favour efficiency in pursuing business growth. In an era of zero-cost money, a surplus of labour and an economic tailwind, the issue of productivity was primarily addressed indirectly through the expansionary pursuit of scale: grow bigger and operational leverage would ultimately drive productivity. Direct investments in productivity tools to drive unit economic efficiencies were generally less popular as they were less likely to yield near-term expansionary growth. Furthermore, they often carried a risk of disrupting an organisation as old processes and workflows are ripped and replaced.

We sense that the broad premise of technology adaptation sitting outside of conventional cyclicality still holds. But we would concede that the dynamics of growth and business scaling are adapting to the higher direct costs of expansion (e.g. higher borrowing costs and wage inflation). Technology companies are among the first to adjust to this, mainly because they were also the ones at the forefront of pursuing expansionary- based scale.

We should not confuse this as being the end of a technology cycle, far from it. As the focus shifts from the pursuit of scale towards tools of efficiency, we think companies that offer or exploit deep productivity- enhancing solutions will come to the fore. You might argue that this has long been the case (e.g. the rise of software tools since the 80s) but productivity growth in most major developed market economies has been lacklustre for several decades1. With looming huge improvements in intelligent automation as discussed below, the prospects for meaningful productivity gains look much brighter and we see the role of automation shifting from the current model of assisting humans with mundane tasks towards more value-added assistance or task displacement.

You will have likely heard about some of the recent advances in AI, particularly in the field of generative AI and local language models through tools such as ChatGPT. While AI and machine learning have been in their ascendency in recent years, their relevance has primarily centred upon narrow probabilistic prediction - with the accuracy of that prediction being most influenced by the intrinsic data quality and manual labelling of data used to train a specific algorithm.

Generative AI is focused on building novel content like art, an essay, or lines of code. When challenged, a sophisticated generative AI engine will draw upon the vast breadth of data it has been exposed to, generate an approximate answer and then seek to refine this through critical challenge. Such an iterative process distances generative AI from the narrower predictive AI on several fronts. Strikingly, it can make linkages between discrete observations and deal with areas of ambiguity in what it observes. Moreover, by mimicking mechanisms of natural conscious learning and seeking resolution not statistical perfection, generative AI outputs instinctively feel much more human-like, and it has proven itself to be especially adept at mastering language and dialogue.

At its core, generative AI advances are about delivering context-relevant, digestible outputs that seek to answer real-world queries. Its power can be pointed in many directions, whether creating novel digital content at a hitherto unimaginable scale or as a user-friendly distiller of complexity. The former could see it garner a role in the production of software code or in-silico screening of vast libraries of compounds for use in areas such as drug discovery or battery technology. The latter uniquely positions it to offer a scalable user interface that could ultimately perform various functions such as knowledge search or fully automated customer service. This is fundamentally different from most current technology interfaces which are about delivering blunt and narrow approximations.

What are the implications of all this? Our initial sense is that these impressive but still nascent advances will lay new foundations for how individuals and businesses engage with technology. Much like the arrival of the internet 30 years ago, we see generative AI as a horizontal technology tool that optically lowers the entry barriers within a range of verticals/industries. Traditionally, such a dynamic would be expected to favour nimble disruptors and disadvantage stale incumbents. Yet to borrow further from the experience of internet-based digitisation, while barriers to entry were initially lowered, we suspect that barriers to scale are likely to prove to be much harder to break down and will likely be better determinants when filtering winners from losers within this technology evolution.

While a clear advantage of generative AI is the ability to train it on vast broad data sources, real-world commercial use cases of this technology will likely have a requirement for domain-relevant digital data with which to hone the algorithms. This proprietary data likely exists within businesses that currently cater to their respective end markets. Furthermore, many incumbents (or at least those that remain/have emerged over the past few decades) are digital native businesses - they are unlikely to be refuseniks when experimenting with what AI offers. Taken together our initial view is that for digitally savvy, forward-thinking businesses we suspect that generative AI is more opportunity than a threat. For such companies, this opportunity should be about making deeper engagements with their customers and better leveraging the assets they already have with the prize being to better their offering, take share, and drive deep productivity savings. Given the importance of this topic, we expect it to be a recurring theme in our dialogue with holdings over the coming year.

Portfolio Update

Novocure disclosed encouraging clinical trial results for its tumour-treating technology in lung cancer patients. Most relevantly, Novocure's device appears to be synergistic with immune checkpoint-blocking antibodies, a class of drugs that have emerged as the primary therapeutic backbone in numerous cancer treatment regimes. Exact Sciences received a boost when an aspiring competitor in the colon cancer screening area revealed the underwhelming performance of its blood-based test. This was further bolstered through encouraging progress from Exact in bringing forward its profitability and targets.

As at 30 April 2023 the Company's investment in unlisted companies was 20.9% of total assets and the names held were unchanged versus 31 October 2022. The end of the period saw both of the portfolio's rocket companies begin test-flight campaigns on the next generation of launch vehicles. SpaceX debuted its massive Starship stack and Relativity Space its entirely 3D-printed Terran-1 rocket. Both are following a rapidly iterative and intentionally destructive development process in order to deliver significant cost and capability improvements in the years ahead. More recently, Astranis, the next-generation satellite company, has launched its first MicroGEO platform into orbit over Alaska where it will triple the available satellite bandwidth.

We remain broadly happy with how the portfolio companies are navigating the current environment and have invested gearing of 12%. However, we have seen a handful of holdings experience large negative price moves following company-specific challenges. Trupanion's profitability has been hit as high levels of inflation in veterinary bills have been hard to pass on via insurance premium increases. Chegg's growth has been impacted by two years of pandemic-impacted enrolment in the US college system. While we expect this to ultimately wash through, the picture has been further complicated by some college students experimenting with generative AI tools for homework and coursework. Kroger, Ocado's grocery partner in the US, announced that it is not planning to open any additional Ocado-powered facilities in 2023 as it digests the lessons from its initial warehouse deployments. With Kroger currently engaged in a proposed merger with its competitor Alberstons (a move that will give it a meaningful expansion in its store base and national presence) we suspect commitments to additional facilities will be pushed back until after the merger completes.

We took a holding in Hashicorp, a provider of cloud infrastructure automation and management tools. It designs cloud-agnostic products which span the entire spectrum of cloud infrastructure automation - from infrastructure provisioning to networking, security, and application deployment - and make it easy for companies to build in the cloud in a standardised and efficient manner. It benefits from powerful secular trends, such as the continued digital transformations of IT systems across industries and the shift to a hybrid or a multi-cloud environment which are inherently complex processes.

We added to the holdings in Novocure, Schrödinger, Progyny and Appian as we felt the stock market was failing to keep pace with the strategic progress these companies are demonstrating. We exited four positions during the interim period including Galapagos, Morphosys, Temenos and Oxford Instruments.

 

1 Since 2005, US labour productivity has grown at a modest 1.4% per annum. In 2022 it dipped to -1.3%, its weakest since 1974.

* Net asset value after deducting borrowings at fair value.

Source: Baillie Gifford, Refinitive and relevant underlying index providers. See disclaimer at the end of this announcement.

The principal risks and uncertainties facing the Company are set out below.

 

For a definition of terms see Glossary of Terms and Alternative Performance Measures.

Total return information sourced from Refinitiv/Baillie Gifford and relevant underlying index providers.

Past performance is not a guide to future performance.

 

Valuing Private Companies

We aim to hold our private company investments at 'fair value' i.e., the price that would be paid in an open-market transaction. Valuations are adjusted both during regular valuation cycles and on an ad hoc basis in response to 'trigger events'. Our valuation process ensures that private companies are valued in both a fair and timely manner.

The valuation process is overseen by a valuations committee at Baillie Gifford which takes advice from an independent third party (S&P Global). The portfolio managers feed into the process, but the valuations committee owns the process and the portfolio managers only receive final valuation notifications once they have been applied.

We revalue the private holdings on a three-month rolling cycle, with one-third of the holdings reassessed each month. For investment trusts, the prices are also reviewed twice per year by the respective investment trust boards and are subject to the scrutiny of external auditors in the annual audit process.

Beyond the regular cycle, the valuations committee also monitors the portfolio for certain 'trigger events'. These may include: changes in fundamentals; a takeover approach; an intention to carry out an Initial Public Offering 'IPO'; or changes to the valuation of comparable public companies. Any ad hoc change to the fair valuation of any holding is implemented swiftly and reflected in the next published net asset value. There is no delay.

The valuations committee also monitors relevant market indices on a weekly basis and updates valuations in a manner consistent with our external valuer's (S&P Global) most recent valuation report where appropriate. When market volatility is particularly pronounced the team undertakes these checks daily.

Recent market volatility has meant that recent pricing has moved much more frequently than would have been the case with the quarterly valuations cycle.

 

Edinburgh Worldwide Investment Trust*


Instruments valued

25

Quantum of individual (lines of stock) reviewed

65

Quantum of revaluations post review

51

Percentage of portfolio revalued 2+ times

100%

Percentage of portfolio revalued 3+ times

52%

* Data reflecting period 1 November 2022 to 30 April 2023 to align with the Company's reporting period end.

 

A handful of companies have raised capital at an increased valuation, reflecting exceptional performance. The average movement in both valuation and share price for those which have decreased in value is shown below.

 

 

Average Movement in Investee Company Valuation

Average Movement in Investee Company Share Price

Instruments valued

1.9%

(1.4%)

 

Data reflecting period 1 November 2022 - 30 April 2023 to align with the Trust's half-year reporting period.

 

Share prices have decreased more than headline valuations which have increased slightly on average, which is partially a result of holding classes of stock with less preferential liquidation rights and therefore less downside protection.

 

The share price movement reflects a probability weighted average of both the regular valuation, which would be realised in an IPO, and the downside protected valuation, which would normally be triggered in the event of a corporate sale or liquidation.

 

The following chart quantifies the movements over the period influencing the fair value of the private company investments at 30 April 2023.

 

 

Baillie Gifford Statement on Stewardship

 

Reclaiming Activism for Long-Term Investors

Baillie Gifford's over-arching ethos is that we are 'actual' investors. We have a responsibility to behave as supportive and constructively engaged long-term investors. We invest in companies at different stages in their evolution, across vastly different industries and geographies and we celebrate their uniqueness. Consequently, we are wary of prescriptive policies and rules, believing that these often run counter to thoughtful and beneficial corporate stewardship. Our approach favours a small number of simple principles which help shape our interactions with companies.

 

Our Stewardship Principles

 

Prioritisation of Long-Term Value Creation

We encourage company management and their boards to be ambitious and focus their investments on long-term value creation. We understand that it is easy for businesses to be influenced by short-sighted demands for profit maximisation but believe these often lead to sub-optimal long-term outcomes. We regard it as our responsibility to steer businesses away from destructive financial engineering towards activities that create genuine economic value over the long run. We are happy that our value will often be in supporting management when others do not.

 

A Constructive and Purposeful Board

We believe that boards play a key role in supporting corporate success and representing the interests of minority shareholders. There is no fixed formula, but it is our expectation that boards have the resources, cognitive diversity and information they need to fulfil these responsibilities. We believe that a board works best when there is strong independent representation able to assist, advise and constructively test the thinking of management.

 

Long-Term Focused Remuneration with Stretching Targets

We look for remuneration policies that are simple, transparent and reward superior strategic and operational endeavour. We believe incentive schemes can be important in driving behaviour, and we encourage policies which create alignment with genuine long-term shareholders. We are accepting of significant pay-outs to executives if these are commensurate with outstanding long-run value creation, but plans should not reward mediocre outcomes. We think that performance hurdles should be skewed towards long-term results and that remuneration plans should be subject to shareholder approval.

 

Fair Treatment of Stakeholders

We believe it is in the long-term interests of all enterprises to maintain strong relationships with all stakeholders - employees, customers, suppliers, regulators and the communities they exist within. We do not believe in one-size-fits all policies and recognise that operating policies, governance and ownership structures may need to vary according to circumstance. Nonetheless, we believe the principles of fairness, transparency and respect should be prioritised at all times.

 

Sustainable Business Practices

We believe an entity's long-term success is dependent on maintaining its social licence to operate and look for holdings to work within the spirit and not just the letter of the laws and regulations that govern them. We expect all holdings to consider how their actions impact society, both directly and indirectly, and encourage the development of thoughtful environmental practices and 'net-zero' aligned climate strategies as a matter of priority. Climate change, environmental impact, social inclusion, tax and fair treatment of employees should be addressed at board level, with appropriately stretching policies and targets focused on the relevant material dimensions. Boards and senior management should understand, regularly review and disclose information relevant to such targets publicly, alongside plans for ongoing improvement.

 

Income Statement (unaudited)

 

For the six months ended 30 April 2023

For the six months ended 30 April 2022

For the year ended 31 October 2022 (audited)

 

Revenue

£'000

Capital

£'000

Total

£'000

Revenue

£'000

Capital

£'000

Total

£'000

Revenue

£'000

Capital

£'000

Total

£'000

Gains on sales of investments

322 

322 

-

42,613

42,613

66,140 

66,140 

Movements in investment holding gains

(59,741)

(59,741)

-

(494,803)

(494,803)

(594,419)

(594,419)

Currency gains/(losses)

5,747 

5,747

-

(2,230)

(2,230)

(6,070)

(6,070)

Income from investments and interest receivable

612 

612 

490

-

490

986 

986 

Investment management fee (note 3)

(563)

(1,690)

(2,253)

(685)

(2,054)

(2,739)

(1,277)

(3,830)

(5,107)

Other administrative expenses

(512)

(512)

(521)

-

(521)

(953)

(953)

Net return before finance costs and taxation

(463)

(55,362)

(55,825)

(716)

(456,474)

(457,190)

(1,244)

(538,179)

(539,423)

Finance costs of borrowings

(720)

(2,160)

(2,880)

(221)

(662)

(883)

(675)

(2,026)

(2,701)

Net return before taxation

(1,183)

(57,522)

(58,705)

(937)

(457,136)

(458,073)

(1,919)

(540,205)

(542,124)

Tax

(26)

(26)

(23)

-

(23)

(57)

(57)

Net return after taxation

(1,209)

(57,522)

(58,731)

(960)

(457,136)

(458,096)

(1,976)

(540,205)

(542,181)

Net return per ordinary share (note 4)

(0.31p)

(14.72p)

(15.03p)

(0.23p)

(112.80p)

(113.03p)

(0.49p)

(134.82p)

(135.31p)

 

The total column of this Statement represents the profit and loss account of the Company. The supplementary revenue and capital columns are prepared under guidance published by the Association of Investment Companies.

 

All revenue and capital items in this Statement derive from continuing operations.

 

A Statement of Comprehensive Income is not required as the Company does not have any other comprehensive income and the net return after taxation is both the profit and comprehensive income for the period.

 

 

Balance Sheet (unaudited)

 

 

 

At 30 April

2023

 

£'000

At 31 October

2022

(audited)

£'000

Fixed assets



Investments held at fair value through profit or loss (note 6)

 802,024

872,804

Current assets



Debtors

7,983

4,882

Cash and cash equivalents

10,349

11,131


18,332

16,013

Creditors



Amounts falling due within one year (note 7)

(108,591)

(113,251)

Net current liabilities

(90,259)

(97,238)

Net assets

711,765

775,566

Capital and reserves



Share capital

4,058

4,058

Share premium account

499,723

499,723

Special reserve

35,220

35,220

Capital reserve

180,062

242,654

Revenue reserve

(7,298)

(6,089)

Shareholders' funds

711,765

775,566

Net asset value per ordinary share

182.78p

197.70p

Ordinary shares in issue (note 8)

389,419,641

392,285,023

 

 

Statement of Changes in Equity (unaudited)

 

For the six months ended 30 April 2023


Share capital

£'000

Share premium account £'000

Special reserve

£'000

Capital reserve*

£'000

Revenue reserve

£'000

Shareholders' funds

£'000

Shareholders' funds at 1 November 2022

4,058

499,723

35,220

242,654 

(6,089)

775,566 

Ordinary shares bought back (note 8)

-

-

-

(5,070)

(5,070)

Net return after taxation

-

-

-

(57,522)

(1,209)

(58,731)

Shareholders' funds at 30 April 2023

4,058

499,723

35,220

180,062 

(7,298)

711,765 

 

 

For the six months ended 30 April 2022


Share capital

£'000

Share premium account £'000

Special reserve

£'000

Capital reserve*

£'000

Revenue reserve

£'000

Shareholders' funds

£'000

Shareholders' funds at 1 November 2021

4,052

497,999

35,220

808,197 

(4,113)

1,341,355 

Ordinary shares bought back (note 8)

6

1,724

-

(7,487)

(5,757)

Net return after taxation

-

-

-

(457,136)

(960)

(458,096)

Shareholders' funds at 30 April 2022

4,058

499,723

35,220

343,574 

(5,073)

877,502 

* The Capital Reserve as at 30 April 2023 includes investment holding losses of £62,965,000 (30 April 2022 - gains of £96,393,000)

 

Condensed Cash Flow Statement (unaudited)

 

 

 

Six months to

 30 April

2023

£'000

Six months to

 30 April

2022

£'000

Cash flows from operating activities



Net return before taxation

(58,705)

(458,073)

Net losses on investments

59,419

452,190

Currency (gains)/losses

(5,747)

 2,230

Finance costs of borrowings

2,880

 883

Overseas withholding tax incurred

(21)

(20)

Changes in debtors and creditors

(81)

(589)

Cash from operations*

(2,255)

(3,379)

Interest paid

(2,526)

(827)

Net cash outflow from operating activities

(4,781)

(4,206)

Net cash inflow/(outflow)from investing activities

10,582

(18,380)

Financing



Ordinary shares bought back

(5,503)

(5,108)

Bank loans drawn down

198,589

 135,346

Bank loans repaid

(200,000)

(135,346)

Net cash outflow from financing activities

(6,914)

(5,108)

Decrease in cash and cash equivalents

(1,113)

(27,694)

Exchange movements

331

 1,301

Cash and cash equivalents at start of period

11,131

 33,127

Cash and cash equivalents at end of period

10,349

 6,734

* Cash from operations includes dividends received in the period of £382,000 (30 April 2022 - £503,000).

Cash and cash equivalents represent cash at bank and short term money market deposits repayable on demand.

 

 

 

Performance of the Top 20 Holdings as at 30 April 2023 (unaudited)

 






Performance

Name

Business

Country

Value

£'000

% of total assets*

Absolute

%

Relative

%

Space Exploration Technologies u #

Designs, manufactures and launches advanced rockets and spacecraft

USA

63,341

7.8

30.0 

32.0 

Alylam Pharmaceuticals

Drug developer focused on harnessing gene silencing technology

USA

57,250

7.1

49.2 

51.5 

PsiQuantum u #

Developer of commercial quantum computing

USA

28,939

3.5

(26.2)

(23.6)

STAAR Surgical

Ophthalmic implants for vision correction

USA

28,218

3.5

23.3 

25.1 

MarketAxess

Electronic bond trading platform

USA

26,775

3.3

21.6 

23.4 

Exact Sciences

Non-invasive molecular tests for early cancer detection

USA

26,427

3.3

15.6 

17.4 

Novocure

Manufacturer of medical devices for cancer treatment

USA

25,554

3.2

(14.1)

(12.8)

Zillow#

US online real estate portal

USA

23,305

2.9

19.8 

23.0 

Ocado

Online grocery retailer and technology provider

UK

22,370

2.8

(44.6)

(43.8)

Axon Enterprises

Law enforcement equipment and software provider

USA

22,177

2.7

87.6 

90.4 

Genmab

Antibody based drug development

Denmark

18,068

2.2

15.8 

17.5 

AeroVironment

Small unmanned aircraft and tactical missile systems

USA

17,654

2.2

25.2 

27.1 

Oxford Nanopore Technologies p

Novel DNA sequencing technology

UK

15,276

1.9

(25.1)

(24.0)

Schrödinger

Drug discovery ad simulation software

USA

12,640

1.6

18.7 

20.5 

Kingdee International Software

Enterprise management software provider

China

12,409

1.5

(26.6)

(25.5)

PureTech Health

IP commercialisation focused on healthcare

UK

12,074

1.5

21.4 

23.2 

Chegg

Online educational company

USA

11,884

1.4

(27.4)

(26.3)

Shine Technologies (Illuminated Holdings) u #

Medical radioisotope production

USA

11,404

1.4

(14.1)

(13.3)

BlackLine

Enterprise financial software provider

USA

10,584

1.3

(17.1)

(15.9)

Pacira BioSciences

Opioid free analgesics developer

USA

10,464

1.3

(39.2)

(38.3)




456,813

56.5



*     Total assets before deduction of loans.

†    Absolute and relative performance has been calculated on a total return basis over the period 1 November 2022 to 30 April 2023. Absolute performance is in sterling terms; relative performance is against S&P Global Small Cap Index (in sterling terms). Source: Baillie Gifford/StatPro and relevant underlying index providers. See disclaimer at the end of this announcement. Denotes private company (unlisted) security.

u Denotes private company (unlisted) security

# More than one line of stock held. Holding information represents the aggregate of all lines of stock.

Past performance is not a guide to future performance.

 

 

 

List of Investments as at 30 April 2023 (unaudited)

 

Name

Business

Country


Value

% of total assets

Space Exploration Technologies Series N Preferred u

Designs, manufactures and launches advanced rockets and spacecraft

USA


 36,303

4.5

Space Exploration Technologies Series J Preferred u

Designs, manufactures and launches advanced rockets and spacecraft

USA


 16,468

2.0

Space Exploration Technologies Series K Preferred u

Designs, manufactures and launches advanced rockets and spacecraft

USA


 7,507

0.9

Space Exploration Technologies Class A Common u

Designs, manufactures and launches advanced rockets and spacecraft

USA


 2,341

0.3

Space Exploration Technologies Class C Common u

Designs, manufactures and launches advanced rockets and spacecraft

USA


 722

0.1





 63,341

7.8

Alnylam Pharmaceuticals

Drug developer focused on harnessing gene silencing technology

USA


 57,250

7.1

PsiQuantum Series C Preferredu

Developer of commercial quantum computing

USA


 16,391

2.0

PsiQuantum Series D Preferred u

Developer of commercial quantum computing

USA


 12,548

1.5





 28,939

3.5

STAAR Surgical

Ophthalmic implants for vision correction

USA


 28,218

3.5

MarketAxess

Electronic bond trading platform

USA


 26,775

3.3

Exact Sciences

Non-invasive molecular tests for early cancer detection

USA


 26,427

3.3

Novocure

Manufacturer of medical devices for cancer treatment

USA


 25,554

3.2

Zillow Class C

US online real estate portal

USA


 20,215

2.5

Zillow Class A

US online real estate portal

USA


 3,090

0.4





 23,305

2.9

Ocado

Online grocery retailer and technology provider

UK


 22,370

2.8

Axon Enterprise

Law enforcement equipment and software provider

USA


 22,177

2.7

Genmab

Antibody based drug development

Denmark


 18,068

2.2

AeroVironment

Small unmanned aircraft and tactical missile systems

USA


 17,654

2.2

Oxford Nanopore Technologies

Novel DNA sequencing technology

UK


 15,276

1.9

Schrödinger

Drug discovery and simulation software

USA


 12,640

1.6

Kingdee International Software

Enterprise management software provider

China


 12,409

1.5

PureTech Health

IP commercialisation focused on healthcare

UK


 12,074

1.5

Chegg

Online educational company

USA


 11,884

1.4

Shine Technologies (Illuminated Holdings) Series C-5 Preferred u

Medical radioisotope production

USA


 10,608

1.3

Shine Technologies (Illuminated Holdings) Series D-1 Preferred u

Medical radioisotope production

USA


 796

0.1





 11,404

1.4

BlackLine

Enterprise financial software provider

USA


 10,584

1.3

Pacira BioSciences

Opioid free analgesics developer

USA


 10,464

1.3

Astranis SpaceTechnologies Series C Preferredu

Communication satellite manufacturing and operation

USA


 9,547

1.2

Astranis Space Technologies Series C Preferred u

Communication satellite manufacturing and operation

USA


 796

0.1





 10,343

1.3

Upwork

Online freelancing and recruitment services platform

USA


 9,928

1.2

Sprout Social

Cloud based software for social media management

USA


 9,624

1.2

Fiverr

Freelance services marketplace for businesses

Israel


 9,399

1.2

ShockWave Medical

Medical devices manufacturer

USA


 9,357

1.2

Appian

Enterprise software developer

USA


 9,170

1.1

Zai Lab HK Line

Chinese bio-pharmaceutical development and distribution company

China


 8,515

1.1

Reaction Engines u

Advanced heat exchange company

UK


 8,351

1.0

IPG Photonics

High-power fibre lasers

USA


 8,260

1.0

Progyny

Fertility benefits management company

USA


 8,234

1.0

Relativity Space Series D Preferred u

3D printing and aerospace launch company

USA


 5,093

0.6

Relativity Space Series E Preferred u

3D printing and aerospace launch company

USA


 3,066

0.4





 8,159

1.0

Xero

Cloud based accounting software for small and medium-sized enterprises

New Zealand


 8,087

1.0

Epic Games u

Video game platform and software developer

USA


 7,411

0.9

Adaptimmune Therapeutics ADR

Cell therapies for cancer treatment

UK


 7,138

0.9

Doximity

Online healthcare resource and interactive
 platform developer

USA


 7,036

0.9

TransMedics

Medical device company

USA


 6,714

0.8

Ceres Power Holding

Developer of fuel cells

UK


 6,600

0.8

Echodyne Corp. Series C-1 Preferred u

Metamaterial radar sensors and software

USA


 6,103

0.8

Snyk Series F Preferred u

Security software

UK


 4,005

0.5

Snyk Ordinary Shares u

Security software

UK


 2,390

0.3





 6,395

0.8

Teladoc

Telemedicine services provider

USA


 6,274

0.8

Genus

Livestock breeding and technology services

UK


 6,238

0.8

Avacta Group

Affinity based diagnostic reagents and therapeutics

UK


 6,218

0.8

LiveRamp

Marketing technology company

USA


 6,200

0.8

JFrog

Software development tools and management

Israel


 6,108

0.8

CyberArk Software

Cyber security solutions provider

Israel


 5,707

0.7

Lightning Labs Series B Preferred u

Lightning software that enables users to send and receive money

USA


 5,458

0.7

HashiCorp

Cloud-computing infrastructure provider

USA


 5,273

0.7

Trupanion

Pet health insurance provider

USA


 5,162

0.6

QuantumScape

Solid-state batteries for electric vehicles

USA


 5,086

0.6

Renishaw

Measurement and calibration equipment

UK


 5,070

0.6

Codexis

Industrial and pharmaceutical enzyme developer

USA


 4,980

0.6

AbCellera Biologics

Antibody design and development company

Canada


 4,956

0.6

Sensirion Holding

Manufacturer of gas and flow sensors

Switzerland


 4,874

0.6

Zuora

Enterprise sales management software

USA


 4,837

0.6

Ambarella

Video compression and image processing semiconductors

USA


 4,812

0.6

Tandem Diabetes Care

Manufacturer of insulin pumps for diabetic patients

USA


 4,671

0.6

BillionToOne Series C Preferred u

Pre-natal diagnostics

USA


 4,125

0.5

BillionToOne Promissory Note u

Pre-natal diagnostics

USA


 398

0.0





 4,523

0.5

M3

Online medical database

Japan


 4,403

0.5

Rightmove

UK online property portal

UK


 3,962

0.5

Splunk

Data diagnostics

USA


 3,769

0.5

MonotaRO

Online business supplies

Japan


 3,765

0.5

PeptiDream

Peptide based drug discovery platform

Japan


 3,696

0.5

DNA Script Series C Preferred u

Synthetic DNA fabricator

France


 3,392

0.4

Everbridge

Critical event management software provider

USA


 3,103

0.4

IP Group

Intellectual property commercialisation

UK


 3,076

0.4

KSQ Therapeutics Series C Preferred u

Biotechnology target identification company

USA


 3,072

0.4

freee K.K.

Cloud based accounting software for small and medium-sized enterprises

Japan


 2,967

0.4

Beam Therapeutics

Biotechnology company

USA


 2,843

0.3

Akili Interactive

Digital medicine company

USA


 2,827

0.3

ITM Power

Hydrogen energy solutions manufacturer

UK


 2,724

0.3

Twist Bioscience

Biotechnology company

USA


 2,708

0.3

InfoMart

Online platform for restaurant supplies

Japan


 2,634

0.3

Sutro Biopharma

Biotechnology company focused on next generation protein therapeutics

USA


 2,538

0.3

American Superconductor

Designs and manufactures power systems and superconducting wire

USA


 2,462

0.3

LendingTree

Online consumer finance marketplace

USA


 2,217

0.3

Ilika

Discovery and development of novel materials for mass market applications

UK


 2,179

0.3

Expensify

Expense management software

USA


 2,160

0.3

Victrex

High-performance thermo-plastics

UK


 2,130

0.3

Quanterix

Ultra-sensitive protein analysers

USA


 2,107

0.3

Digimarc

Digital watermarking technology provider

USA


 2,097

0.3

Graphcore Series D2 Preferred u

Specialised processor chips for machine learning applications

UK


 1,518

0.2

Graphcore Series E Preferred u

Specialised processor chips for machine learning applications

UK


 484

0.1





 2,002

0.3

New Horizon Health

Cancer screening company

China


 1,996

0.2

Chinook Therapeutics

Immunotherapy drug development

USA


 1,861

0.2

Chinook Therapeutics CVR Line

Immunotherapy drug development

USA


 0

0.0





 1,861

0.2

Stratasys

3D printer manufacturer

USA


 1,652

0.2

Cosmo Pharmaceuticals

Therapies for gastrointestinal diseases

Italy


 1,608

0.2

C4X Discovery Holdings

Rational drug design and optimisation

UK


 1,607

0.2

C4X Discovery Warrants

Software to aid drug design

UK


 -

0.0





 1,607

0.2

Huya ADR

A live game streaming platform

China


 1,606

0.2

Q2 Holdings

Cloud based virtual banking solutions provider

USA


 1,599

0.2

CEVA

Licenses IP to the semiconductor industry

USA


 1,516

0.2

Cardlytics

Digital advertising platform

USA


 1,366

0.1

EverQuote

Online marketplace for buying insurance

USA


 1,280

0.1

Wayfair

Online furniture and homeware retailer

USA


 1,119

0.1

BASE

Commerce platform for small and medium-sized enterprises

Japan


 1,117

0.1

Tabula Rasa HealthCare

Cloud-based healthcare software developer

USA


 1,027

0.1

LivePerson

Messaging tools for business and customer interactions

USA


 909

0.1

Nanobiotix ADR

Nanomedicine company focused on cancer radiotherapy

France


 896

0.1

NuCana SPN ADR

Next generation chemotherapy developer

UK


 828

0.1

Catapult Group International

Analytics and data collection technology for sports teams and athletes

Australia


 741

0.1

Agora ADR

Voice and video platform technology provider

China


 680

0.1

Cellectis

Genetic engineering for cell based therapies

France


 367

0.1

Cellectis ADR

Genetic engineering for cell based therapies

France


 127

<0.1





 494

0.1

Spire Global

Satellite powered data collection and analysis company

USA


 478

0.1

Adicet Bio (formerly resTORbio)

Biotechnology company focused on age related disorders

USA


 409

0.1

Phenomex

Biotechnology tools focused on cell characterisation

USA


 230

<0.1

Angelalign Technology

Medical devices manufacturer

China


 88

<0.1

4D Pharma

Microbiome biology therapeutics

UK


0

0.0

4D Pharma Warrants

Microbiome biology therapeutics

UK


0

0.0





0

0.0

China Lumena New Materials S

Mines, processes and manufactures natural thenardite products

China


0

0.0

Total investments

 

 


802,024

99.2

Net liquid assets

 

 


6,741

0.8

Total assets




808,765

100.0

 

* Total assets before deduction of loans.

u Denotes unlisted security.

P  Denotes security where majority of holding was previously held in the portfolio as an unlisted security.

S Denotes suspended security.

 


Listed equities

%

Unlisted securities #

%

 

Net liquid assets

%

Total assets

%

30 April 2023

78.3

20.9

0.8

100.0

31 October 2022

79.2

20.1

0.7

100.0

Figures represent percentage of total assets.

# Includes holdings in ordinary shares and preference shares.

 

 

Distribution of Total Assets* (unaudited)

 

Industry Analysis at 30 April 2023

% of total assets*

Portfolio Weightings (relative to comparative index) %

Biotechnology

20.4

16.8

Aerospace and Defence

14.6

13.3

Software

14.0

9.9

Healthcare Equipment and Supplies

9.1

6.8

Healthcare Technology

4.2

3.9

Technology Hardware, Storage and Peripherals

4.0

3.4

Capital Markets

3.7

0.8

Life Sciences Tools and Services

3.6

2.6

Electronic Equipment, Instruments and Components

3.1

0.6

Electrical Equipment

3.0

1.4

Pharmaceuticals

2.9

1.0

Real Estate Management and Development

2.8

1.1

Professional Services

2.7

0.7

Food and Staples Retailing

2.7

1.5

Healthcare Providers and Services

1.8

-0.2

Diversified Consumer Services

1.3

0.6

Semiconductors and Semiconductor Equipment

0.8

-1.8

Interactive Media and Services

0.6

0.0

Auto Components

0.5

-0.9

Insurance

0.5

-2.3

Trading Companies and Distributors

0.5

-1.0

Consumer Finance

0.3

-0.4

Chemicals

0.3

-3.0

Entertainment

0.2

-0.6

Specialty Retail

0.2

-2.3

Media

0.2

-1.3

IT Services

0.1

-1.2

Net Liquid Assets

0.8

0.8

* Total assets before deduction of loans.

 S&P Global Small Cap Index. Weightings exclude industries where the Company has no exposure. See disclaimer at the end of this announcement.

 

 

Geographical Analysis

30 April 2023

%

31 October 2022

%

North America

72.1

71.7

USA                    

71.5

70.6

Canada

0.6

1.1

Europe

20.6

21.5

United Kingdom

14.3

13.5

Eurozone

3.0

1.8

Developed Europe (non euro)

3.3

6.2

Asia

5.4

5.0

Japan

3.1

2.3

China

2.3

2.7

Australasia

1.1

1.1

Australia

0.1

0.1

New Zealand

1.0

1.0

0.8

0.7

100.0

100.0

 

Sectoral Analysis

30 April 2023

%

31 October 2022

%

Communication Services

3.8

2.9

Consumer Discretionary

4.9

6.3

Financials

4.6

4.3

Healthcare

42.2

43.2

Industrials

21.0

17.7

Information Technology

22.4

24.7

Materials

0.3

0.2

Net Liquid Assets

0.8

0.7

Total Assets

100.0

100.0

 

Notes to the Financial Statements (unaudited)

1.   The condensed Financial Statements for the six months to 30 April 2023 comprise the statements set out above together with the related notes below. They have been prepared in accordance with FRS 104 'Interim Financial Reporting' and the AIC's Statement of Recommended Practice issued in October 2019 and updated in July 2022 with consequential amendments. They have not been audited or reviewed by the Auditor pursuant to the Auditing Practices Board Guidance on 'Review of Interim Financial Information'. The Financial Statements for the six months to 30 April 2023 have been prepared on the basis of the same accounting policies as set out in the Company's Annual Report and Financial Statements at 31 October 2022.

 

Going Concern

The Directors have considered the nature of the Company's principal risks and uncertainties, as set out on the inside front cover. In addition, the Company's investment objective and policy, assets and liabilities, and projected income and expenditure, together with the dividend policy have been taken into consideration and it is the Directors' opinion that the Company has adequate resources to continue in operational existence for the foreseeable future. The Board has, in particular, considered the ongoing impact of geopolitical and macroeconomic challenges. The Company's assets, the majority of which are investments in quoted securities which are readily realisable, exceed its liabilities significantly.

All borrowings require the prior approval of the Board. Gearing levels and compliance with borrowing covenants are reviewed by the Board on a regular basis. The Company has continued to comply with the investment trust status requirements of section 1158 of the Corporation Tax Act 2010 and the Investment Trust (Approved Company) (Tax) Regulations 2011. Accordingly, the Directors consider it appropriate to adopt the going concern basis of accounting in preparing these Financial Statements and confirm that they are not aware of any material uncertainties which may affect the Company's ability to continue to do so over a period of at least twelve months from the date of approval of these Financial Statements.

 

2.   The financial information contained within this Interim Financial Report does not constitute statutory accounts as defined in sections 434 to 436 of the Companies Act 2006. The financial information for the year ended 31 October 2022 has been extracted from the statutory accounts which have been filed with the Registrar of Companies. The Auditor's Report on those accounts was not qualified, did not include a reference to any matters to which the Auditor drew attention by way of emphasis without qualifying the report, and did not contain a statement under sections 498(2) or (3) of the Companies Act 2006.

 

3.   Baillie Gifford & Co Limited, a wholly owned subsidiary of Baillie Gifford & Co, has been appointed by the Company as its Alternative Investment Fund Manager and Company Secretary. The investment management function has been delegated to Baillie Gifford & Co. Dealing activity and transaction reporting have been further sub-delegated to Baillie Gifford Overseas Limited and Baillie Gifford Asia (Hong Kong) Limited. The management agreement is terminable on not less than three months' notice. The annual management fee is 0.75% on the first £50 million of net assets, 0.65% on the next £200 million of net assets and 0.55% on the remaining net assets.

 

4.   Net return per ordinary share


Six months

to 30 April

2023

 

£'000

Six months

to 30 April

2022

 

£'000

Year to

31 October

2022

(audited)

£'000

Net return per ordinary share




Revenue return after taxation

(1,209)

(960)

(1,976)

Capital return after taxation

(57,522)

(457,136)

(540,205)

Total net return

(58,731)

(458,096)

(542,181)

Weighted average number of ordinary shares in issue

390,711,773

 405,267,892

400,679,723

 

5.   Dividend

No interim dividend has been declared.

 

6.  Fair Value Hierarchy

 

The Company's investments are financial assets held at fair value through profit or loss. The fair value hierarchy used to analyse the basis on which the fair values of financial instruments held at fair value through the profit or loss account are measured is described below. Fair value measurements are categorised on the basis of the lowest (that is the least reliable or least independently observable) level input that is significant to the fair value measurement.

Level 1 - using unadjusted quoted prices for identical instruments in an active market;

Level 2 - using inputs, other than quoted prices included within Level 1, that are directly or indirectly observable (based on market data); and

Level 3 - using inputs that are unobservable (for which market data is unavailable).

An analysis of the Company's financial assets based on the fair value hierarchy described above is shown below.

 

Investments held at fair value through profit or loss

 

 

As at 30 April 2023

Level 1

£'000

Level 2

£'000

Level 3

£'000

Total

£'000

Listed equities

 633,131

-

-

633,131

Unlisted ordinary shares

 -

-

21,215

21,215

Unlisted preference shares*

-

-

147,280

147,280

Unlisted promissory note

 -

-

398

398

Total financial asset investments

 633,131

-

168,893

802,024

 

 

As at 31 October 2022 (audited)

Level 1

£'000

Level 2

£'000

Level 3

£'000

Total

£'000

Listed equities

696,135

-

-

696,135

Unlisted ordinary shares

-

-

22,456

22,456

Unlisted preference shares*

-

-

153,779

153,779

Unlisted promissory note

-

-

434

434

Total financial asset investments

696,135

-

176,669

872,804

* The investments in preference shares are not classified as equity holdings as they include liquidation preference rights that determine the repayment (or multiple thereof) of the original investment in the event for a liquidation event such as a take-over

 

There have been no transfers between levels of the fair value hierarchy during the period. The fair value of listed investments is either bid price or, depending on the convention of the exchange on which the investment is listed, last traded price. Listed investments are categorised as Level 1 if they are valued using unadjusted quoted prices for identical instruments in an active market and as Level 2 if they do not meet all these criteria but are, nonetheless, valued using market data. Unlisted investments are valued at fair value by the Directors following a detailed review and appropriate challenge of the valuations proposed by the Managers. The Managers' unlisted investment policy applies methodologies consistent with the International Private Equity and Venture Capital Valuation guidelines ('IPEV'). The principal methodologies can be categorised as follows: (a) market approach (price of recent investment, multiples, industry valuation benchmarks and available market prices); (b) income approach (discounted cash flows); and (c) replacement cost approach (net assets). The Company's holdings in unlisted investments are categorised as Level 3 as unobservable data is a significant input to their fair value measurements.

7.   Bank Loans

At 30 April 2023 creditors falling due within one year include borrowings of £97,000,000 (31 October 2022 - £103,827,000) drawn down under a five year £100 million multi-currency revolving credit facility with The Royal Bank of Scotland International Limited which expires on 9 June 2026.

At 30 April 2023 the drawings were €10,600,000, US$77,150,000 and £26,308,000 (31 October 2022 - €10,600,000, US$77,150,000 and £27,720,000) drawn down under the £100 million multi-currency revolving credit facility.

At 30 April 2023 there were no drawings under the £25 million or £36 million multi-currency revolving credit facilities with National Australia Bank Limited with expiry dates of 29 June 2023 and 30 September 2024 respectively (31 October 2022 - nil).

The fair value of the bank loans at 30 April 2023 was £97,000,000 (31 October 2022 - £103,827,000).

8.   Share Capital

 


30 April
2023

Number

30 April
2023
£'000

31 October
2022

Number

31 October
2022

£'000

Allotted, called up and fully paid ordinary
shares of 1p each

389,419,641

3,894

392,285,023

3,923

Treasury shares of 1p each

16,334,054

164

13,468,672

135


405,753,695

4,058

405,753,695

4,058

 

The Company has authority to allot shares under section 551 of the Companies Act 2006. The Board has authorised use of this authority to issue new shares at a premium to net asset value in order to enhance the net asset value per share for existing shareholders and improve the liquidity of the Company's shares. In the six months to 30 April 2023, no shares were issued (in the six months to 30 April 2022 - 550,000 shares with a nominal value of £6,000, representing 0.1% of the issued share capital at 31 October 2021 raising net proceeds of £1,730,000).

 

Over the period from 30 April 2023 to 6 June 2023 the Company issued no further shares.

 

The Company also has authority to buy back shares. In the six months to 30 April 2023, 2,865,382 shares with a nominal value of £29,000 were bought back at a total cost of £5,070,000 and held in treasury (in the six months to 30 April 2022- 3,525,695 shares were bought back and held in treasury). At 30 April 2023 the Company had authority to buy back a further 58,628,524 ordinary shares.

 

Over the period from 30 April 2023 to 6 June 2023, no further shares have been bought back by the Company.

 

9.   Transaction Costs

During the period the Company incurred transaction costs on purchases of investments of £8,000 (30 April 2022 - £29,000; 31 October 2022 - £155,000) and transaction costs on sales of £3,000 (30 April 2022- £4,000; 31 October 2022 - £25,000).

 

10.  Related Party Transactions

There have been no transactions with related parties during the first six months of the current financial year that have materially affected the financial position or the performance of the Company during that period and there have been no changes in the related party transactions described in the last Annual Report and Financial Statements that could have had such an effect on the Company during that period.

 

None of the views expressed in this document should be construed as advice to buy or sell a particular investment.

 

Principal Risks and Uncertainties

The principal risks facing the Company are financial risk, investment strategy risk, climate and governance risk, discount risk, regulatory risk, custody and depositary risk, small company risk, private company (unlisted) investments risk, operational risk, leverage risk, political and associated economic risk, cyber security risk and emerging risks. An explanation of these risks and how they are managed is set out on pages 9 and 10 of the Company's Annual Report and Financial Statements for the year to 31 October 2022 which is available on the Company's website: edinburghworldwide.co.uk. The principal risks and uncertainties have not changed since the date of the Annual Report.

 

 

Glossary of Terms and Alternative Performance Measures ('APM')

An alternative performance measure is a financial measure of historical or future financial performance, financial position, or cash flows, other than a financial measure defined or specified in the applicable financial reporting framework.

Total Assets

This is the Company's definition of Adjusted Total Assets, being the total value of assets held less all liabilities (other than liabilities in the form of borrowings).

Net Asset Value ('NAV')

Also described as shareholders' funds, net asset value is the value of total assets less liabilities (including borrowings). Net asset value can be calculated on the basis of borrowings stated at book value and fair value. An explanation of each basis is provided below. The net asset value per share is calculated by dividing this amount by the number of ordinary shares in issue excluding any shares held in treasury.

Net Asset Value (Borrowings at Book Value)

Borrowings are valued at nominal book value (book cost).

Net Asset Value (Borrowings at Fair Value) (APM)

Borrowings are valued at an estimate of their market worth.

Net Asset Value (Reconciliation of NAV at Book Value to NAV at Fair Value)

 


30 April 2023

31 October 2022

Net Asset Value per ordinary share (borrowings at book value)

182.78p

197.70p

Shareholders' funds (borrowings at book value)

£711,765,000

£755,566,000

Add: book value of borrowings

£97,000,000

£103,827,000

Less: fair value of borrowings

£97,000,000

(£103,827,000)

Shareholders' funds (borrowings at fair value)

£711,765,000

£775,566,000

Number of shares in issue

389,419,641

392,285,023

Net Asset Value per ordinary share (borrowings at fair value)

182.78p

197.70p

 

Net Asset Value (Reconciliation of NAV at Book Value to NAV at Fair Value)

At 30 April 2023 and 31 October 2022 all borrowings are in the form of short term floating rate borrowings and their fair value is considered equal to their book value, hence there is no difference in the net asset value at book value and fair value.

Net Liquid Assets

Net liquid assets comprise current assets less current liabilities, excluding borrowings.

Discount/Premium (APM)

As stockmarkets and share prices vary, an investment trust's share price is rarely the same as its net asset value. When the share price is lower than the net asset value per share it is said to be trading at a discount. The size of the discount is calculated by subtracting the share price from the net asset value per share and is usually expressed as a percentage of the net asset value per share. If the share price is higher than the net asset value per share, this situation is called a premium.


30 April 2023

31 October 2022

Net Asset Value per share

(a)

182.78p

197.70p

Share price

(b)

149.20p

172.60p

Discount ((b)-(a)) ÷ (a)

(18.4%)

(12.7%)

 

Total Return (APM)

The total return is the return to shareholders after reinvesting the dividend on the date that the share price goes ex-dividend. The Company does not pay a dividend, therefore, the one year total returns for the share price and NAV per share at book and fair value are the same as the percentage movements in the share price and NAV per share at book and fair value.

Ongoing Charges (APM)

The total recurring expenses (excluding the Company's cost of dealing in investments and borrowing costs) incurred by the Company as a percentage of the average net asset value (with debt at fair value). The ongoing charges are calculated on the basis prescribed by the Association of Investment Companies.

Gearing (APM)

At its simplest, gearing is borrowing. Just like any other public company, an investment trust can borrow money to invest in additional investments for its portfolio. The effect of the borrowing on the shareholders' assets is called 'gearing'. If the Company's assets grow, the shareholders' assets grow proportionately more because the debt remains the same. But if the value of the Company's assets falls, the situation is reversed. Gearing can therefore enhance performance in rising markets but can adversely impact performance in falling markets.

Invested gearing is the Company's borrowings at book value less cash and cash equivalents (as adjusted for investment and share buy back/issuance transactions awaiting settlement) expressed as a percentage of shareholders' funds.

 


30 April 2023

31 October 2022

Borrowings (at book value)

£97,000,000 

£103,827,000 

Less: cash and cash equivalents

(£10,349,000)

(£11,131,000)

Less: sales for subsequent settlement

(£7,627,000)

(£4,598,000)

Add: purchases for subsequent settlement

£8,971,000 

£6,719,000 

Add: buy backs awaiting settlement

£433,000 

Adjusted borrowings

(a)

£87,995,000 

£95,250,000 

Shareholders' funds

(b)

£711,765,000 

£775,566,000 

Invested gearing: (a) as a percentage of (b)

12%

12%

 

Potential gearing is the Company's borrowings expressed as a percentage of shareholders' funds.



30 April 2023

31 October 2022

Borrowings (at book value)

(a)

£97,000,000

£103,827,000

Shareholders' funds

(b)

£711,765,000

(£11,131,000)

Potential gearing: (a) as a percentage of (b)


14%

13%

 

Leverage (APM)

For the purposes of the Alternative Investment Fund Managers Directive, leverage is any method which increases the Company's exposure, including the borrowing of cash and the use of derivatives. It is expressed as a ratio between the Company's exposure and its net asset value and can be calculated on a gross and a commitment method. Under the gross method, exposure represents the sum of the Company's positions after the deduction of sterling cash balances, without taking into account any hedging and netting arrangements. Under the commitment method, exposure is calculated without the deduction of sterling cash balances and after certain hedging and netting positions are offset against each other.

Active Share (APM)

Active share, a measure of how actively a portfolio is managed, is the percentage of the portfolio that differs from its comparative index. It is calculated by deducting from 100 the percentage of the portfolio that overlaps with the comparative index. An active share of 100 indicates no overlap with the index and an active share of zero indicates a portfolio that tracks the index.

Treasury Shares

The Company has the authority to make market purchases of its ordinary shares for retention as treasury shares for future reissue, resale, transfer, or for cancellation. Treasury shares do not receive distributions and the Company is not entitled to exercise the voting rights attaching to them.

Private (Unlisted) Company

An unlisted or private company means a company whose shares are not available to the general public for trading and are not listed on a stock exchange.

 

 

Third Party Data Provider Disclaimer

                    

No third party data provider ('Provider') makes any warranty, express or implied, as to the accuracy, completeness or timeliness of the data contained herewith nor as to the results to be obtained by recipients of the data. No Provider shall in any way be liable to any recipient of the data for any inaccuracies, errors or omissions in the index data included in this document, regardless of cause, or for any damages (whether direct or indirect) resulting therefrom.

No Provider has any obligation to update, modify or amend the data or to otherwise notify a recipient thereof in the event that any matter stated herein changes or subsequently becomes inaccurate.

Without limiting the foregoing, no Provider shall have any liability whatsoever to you, whether in contract (including under an indemnity), in tort (including negligence), under a warranty, under statute or otherwise, in respect of any loss or damage suffered by you as a result of or in connection with any opinions, recommendations, forecasts, judgements, or any other conclusions, or any course of action determined, by you or any third party, whether or not based on the content, information or materials contained herein.

S&P Index

The S&P Global Small Cap Index ('Index') is a product of S&P Dow Jones Indices LLC, a division of S&P Global, or its affiliates ('SPDJI'). Standard & Poor's® and S&P® are registered trademarks of Standard & Poor's Financial Services LLC, a division of S&P Global ('S&P'); Dow Jones® is a registered trademark of Dow Jones Trademark Holdings LLC ('Dow Jones'). Neither S&P Dow Jones Indices LLC, Dow Jones Trademark Holdings LLC, their affiliates nor their third party licensors make any representation or warranty, express or implied, as to the ability of any index to accurately represent the asset class or market sector that it purports to represent and neither S&P Dow Jones Indices LLC, Dow Jones Trademark Holdings LLC, their affiliates nor their third party licensors shall have any liability for any errors, omissions, or interruptions of any index or the data included therein.

 

Sustainable Finance Disclosure Regulation ('SFDR')

The EU Sustainable Finance Disclosure Regulation ('SFDR') does not have a direct impact in the UK due to Brexit, however, it applies to third-country products marketed in the EU. As Edinburgh Worldwide Investment Trust plc is marketed in the EU by the AIFM, Baillie Gifford & Co Limited, via the National Private Placement Regime ('NPPR') the following disclosures have been provided to comply with the high-level requirements of SFDR.

 

The AIFM has adopted Baillie Gifford & Co's Governance and Sustainable Principles and Guidelines as its policy on integration of sustainability risks in investment decisions.

 

Baillie Gifford & Co's approach to investment is based on identifying and holding high quality growth businesses that enjoy sustainable competitive advantages in their marketplace. To do this it looks beyond current financial performance, undertaking proprietary research to build up an in-depth knowledge of an individual company and a view on its long-term prospects. This includes the consideration of sustainability factors (environmental, social and/or governance matters) which it believes will positively or negatively influence the financial returns of an investment.

 

More detail on the Investment Manager's approach to sustainability can be found in the Governance and Sustainability Principles and Guidelines document, available publicly on the Baillie Gifford website bailliegifford.com/literature-library/ corporate-governance/our-stewardship- approach-esg-principles-and-guidelines-2023/.

 

Taxonomy Regulation

The Taxonomy Regulation establishes an EU-wide framework or criteria for environmentally sustainable economic activities in respect of six environmental objectives. It builds on the disclosure requirements under SFDR by introducing additional disclosure obligations in respect of AIFs that invest in an economic activity that contributes to an environmental objective.

 

The Company does not commit to make sustainable investments as defined under SFDR. As such, the underlying investments do not take into account the EU criteria for environmentally sustainable economic activities

- Ends -

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100

Latest directors dealings